Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18872558 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1OPRD1FPR3FPR2 | |
| SCHEMBL27353638 | 0.96 | KDM1A (0.48) | SMN1; SMN2ALDH1A1OPRD1FPR3FPR2 | |
| SCHEMBL27353552 | 0.96 | KDM1A (0.48) | SMN1; SMN2ALDH1A1OPRD1FPR3FPR2 | |
| SCHEMBL27353389 | 0.96 | KDM1A (0.48) | SMN1; SMN2ALDH1A1OPRD1FPR3FPR2 | |
| SCHEMBL1237986 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1OPRD1FPR3FPR2 | |
| SCHEMBL15141637 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1OPRD1FPR3FPR2 | |
| SCHEMBL15141639 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1OPRD1FPR3FPR2 | |
| SCHEMBL3040560 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1OPRD1FPR3FPR2 | |
| SCHEMBL190145 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1OPRD1FPR3FPR2 | |
| SCHEMBL5109143 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1OPRD1FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057141-B1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | GSK3B, GSK3A, GSKIP | SMN1; SMN2 2121/4885ALDH1A1 2362/4885OPRD1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.